[go: up one dir, main page]

WO2023104809A3 - 2-oxothiazole compositions for treatment of t-cell acute lymphoblastic leukaemia - Google Patents

2-oxothiazole compositions for treatment of t-cell acute lymphoblastic leukaemia Download PDF

Info

Publication number
WO2023104809A3
WO2023104809A3 PCT/EP2022/084623 EP2022084623W WO2023104809A3 WO 2023104809 A3 WO2023104809 A3 WO 2023104809A3 EP 2022084623 W EP2022084623 W EP 2022084623W WO 2023104809 A3 WO2023104809 A3 WO 2023104809A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
cell acute
oxothiazole
compositions
acute lymphoblastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2022/084623
Other languages
French (fr)
Other versions
WO2023104809A2 (en
Inventor
Astrid Jullumstrø FEUERHERM
Felicity Jane ASHCROFT
Berit Johansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coegin Pharma AB
Original Assignee
Coegin Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coegin Pharma AB filed Critical Coegin Pharma AB
Publication of WO2023104809A2 publication Critical patent/WO2023104809A2/en
Publication of WO2023104809A3 publication Critical patent/WO2023104809A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A compound of formula (I) wherein R6 is H, C1-6alkyl, -(CH2)pCOOH, -(CH2)pCOOC1-6alkyl, - (CH2)pCONH2, -(CH2)pCONHC1-6alkyl, and -(CH2)pCON(C1-6alkyl)2; R11 is H or C1-6 alkyl; R5 is -OC1-10alkyl, -SC1-10alkyl, -C1-12alkyl, or OAr2; wherein Ar2 is phenyl, optionally substituted with one or more halo; each p is 0 to 3; or a salt, ester, solvate, N-oxide, or prodrug thereof, e.g. a salt thereof; for use in the treatment of T-cell acute lymphocytic leukemia.
PCT/EP2022/084623 2021-12-06 2022-12-06 2-oxothiazole compositions for treatment of t-cell acute lymphoblastic leukaemia Ceased WO2023104809A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2117609.4A GB202117609D0 (en) 2021-12-06 2021-12-06 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia
GB2117609.4 2021-12-06

Publications (2)

Publication Number Publication Date
WO2023104809A2 WO2023104809A2 (en) 2023-06-15
WO2023104809A3 true WO2023104809A3 (en) 2023-07-20

Family

ID=80080911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/084623 Ceased WO2023104809A2 (en) 2021-12-06 2022-12-06 2-oxothiazole compositions for treatment of t-cell acute lymphoblastic leukaemia

Country Status (2)

Country Link
GB (1) GB202117609D0 (en)
WO (1) WO2023104809A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014118195A1 (en) * 2013-01-29 2014-08-07 Avexxin As Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
WO2016016472A1 (en) * 2014-08-01 2016-02-04 Avexxin As 2-oxothiatole compounds having activity as cpla2 inhibitors for the treatment of inflammatory disorders and hyperproliferative disorders
US20190142835A1 (en) * 2017-11-14 2019-05-16 Oregon Health & Science University Inhibition of autophagy using phospholipase a2 inhibitors
WO2020229688A1 (en) * 2019-05-15 2020-11-19 Avexxin As Combination therapy for proliferative conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2482815B1 (en) 2009-10-02 2018-05-02 Avexxin AS Antiinflammatory 2-oxothiazoles and 2-oxooxazoles
GB201806663D0 (en) 2018-04-24 2018-06-06 Avexxin As 2-Oxothiazole compositions for treatment of fibrotic disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014118195A1 (en) * 2013-01-29 2014-08-07 Avexxin As Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
WO2016016472A1 (en) * 2014-08-01 2016-02-04 Avexxin As 2-oxothiatole compounds having activity as cpla2 inhibitors for the treatment of inflammatory disorders and hyperproliferative disorders
US20190142835A1 (en) * 2017-11-14 2019-05-16 Oregon Health & Science University Inhibition of autophagy using phospholipase a2 inhibitors
WO2020229688A1 (en) * 2019-05-15 2020-11-19 Avexxin As Combination therapy for proliferative conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAN PUIJENBROEK ANDRÉ A.F.L. ET AL: "PHOSPHOLIPASE A2INHIBITORS AND LEUKOTRIENE SYNTHESIS INHIBITORS BLOCK TNF-INDUCED NF-[kappa]B ACTIVATION", CYTOKINE, vol. 11, no. 2, 1 February 1999 (1999-02-01), US, pages 104 - 110, XP093034379, ISSN: 1043-4666, DOI: 10.1006/cyto.1998.0404 *

Also Published As

Publication number Publication date
WO2023104809A2 (en) 2023-06-15
GB202117609D0 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
MX2021008241A (en) Heterocyclic compound and use thereof.
CR20220613A (en) Microbiocidal derivatives
AU2018312326A2 (en) Heterocyclic compound and use thereof
MX2021006099A (en) Microbiocidal thiazole derivatives.
PH12023553199A1 (en) Microbiocidal tetrahydroisoquinoline derivatives
PH12021550464A1 (en) Isoxazoline compounds for controlling invertebrate pests
EP4458348A3 (en) Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
MX2009010846A (en) Process for producing pesticidal benzamide compounds.
CA3242974A1 (en) LIPID AND COMPOSITION USED FOR ADMINISTRATION
JOP20220085A1 (en) Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers
MX2019014406A (en) Heterocyclic compound and composition containing same.
MX344276B (en) Novel piperidine compound or salt thereof.
MY148653A (en) N, n-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
MX2021013981A (en) Aurora kinase inhibitor and use thereof.
PH12023553237A1 (en) Spiroindolinone compounds as kv1.3 potassium shaker channel blockers
DK2061452T3 (en) Use of caffeic acid and its derivatives against cancer
MX360734B (en) Microbicidal composition comprising a benzoate or sorbate salt.
MX2021011286A (en) Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia.
MX2022008665A (en) Novel pyrazole derivative.
BRPI0514137A (en) use of at least one heterocyclic compound, fuel composition, additives concentrate, and process for preparing a fuel composition
CR20210259A (en) Meta-diamide compounds for controlling invertebrate pests
CA3156981C (en) Aryl heterobicyclic compounds as kv1.3 potassium shaker channel blockers
ZA202301378B (en) Solid form of compound
MX2023011409A (en) Microbiocidal quinoline/quinoxaline benzothiazine derivatives.
MX2020006280A (en) A topical composition based on niacinamide derivative.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22835211

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22835211

Country of ref document: EP

Kind code of ref document: A2